OBJECTIVE： To provide reference for clinical rational use and management of anti-HIV drugs， and to provide reference basis for occupational exposure to develop free drug policy. METHODS： Using retrospective study method， according to DDD calculation method recommended by WHO， consumption sum， DDDs， DDC and B/A of anti-HIV drugs in our center during 2011-2014 were analyzed and evaluated. RESULTS： The consumption sum of anti-HIV drugs increased firstly and decreased later， increasing from 512 112 yuan in 2011 to 650 854 yuan in 2012， decreasing to 496 473 yuan in 2014. DDDs of anti-HIV drugs in our center during 2011-2014 decreased from 35 932 in 2011， to 16 363 in 2014， showing decreasing tendency. The consumption sum of nucleotide reverse transcriptase inhibitors during 2012-2014 took up the first place， and DDDs of nucleotide reverse transcriptase inhibitors took up the first place in 2011， 2013， 2014. DDDs of Zidovudine tablets took up the first place in 2013， 2014， and that of Tangcao tablets took up top 3 places during 2011-2014. DDC of Tenofour disoproxil fumarate tablets， Zidovudine and lamivudine tablets， Emtricitabine and tenofovir tablets， Lopinavir and ritonavir tablets were in high level， being more than 46 yuan. DDC of Zidovudine tablets， Stavadine tablets and Nevirapine tablets were in low level， being lower than 6 yuan. B/A of Tenofovir disoproxil fumarate tablets， Stavudine tablets and Efavirenz tablets ranged 0.5-1.5 in 4 years and B/A of Tangcao tablets was equal to 1， showing good synchronism of social and economical benefits. CONCLUSIONS： Clinical application of anti-HIV drugs in our center is rational basically， and the use of drug is basically consistent with the occupational exposure prevention. The use of TCM preparation is basically in line with the requirements of drug use in the clinic.